Skip to content

vNOTES in Elective Bilateral Salpingectomy for Sterilization

The Use of vNOTES Approach in Elective Bilateral Salpingectomy for Sterilization as a Cancer Prevention Strategy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04809428
Enrollment
98
Registered
2021-03-22
Start date
2021-02-12
Completion date
2021-05-09
Last updated
2021-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sterility, Female

Keywords

vNOTES, Scarless surgery, cancer prevention

Brief summary

Objective: To compare the vNOTES approach versus conventional laparoscopic approach to be used in elective bilateral salpingectomy for sterilisation as an opportunistic cancer prevention strategy. Study design: Prospective cohort, two-centred trial. Study population: All women aged over 18 who are planned to undergo for definitive surgical sterilisation regardless of parity with a non-prolapsed uterus. Primary outcomes: (1) Patient satisfaction (at 1st week and 1st month of the surgery) measured by The Patient Global Imression of Improvement (PGI-I), (2) Postoperative early pain (Visual Analog Score (VAS) at 6th and 24th hours of the surgery). Secondary outcomes: (1) Conversion to laparoscopy or laparotomy, (2) duration of the procedure, (3)total amount of analgesics used, (4) New-onset dyspareunia at first coitus measured by the Pain subdomain of Female Sexual Function Index (FSFI), (5) intraoperative complications, (6) postoperative complications

Detailed description

Women who are indicated or seek for surgical sterilisation are routinely offered salpingectomy rather than tubal ligation for cancer prevention purposes as a local protocol. Those patients will be offered for vNOTES approach after detailed patient counselling and will be enrolled to the study upon acceptation.

Interventions

PROCEDUREvNOTES salpingectomy

Surgical removal of both salpinx by vNOTES with using a 3-cm of posterior colpotomy and either glove port or Gel point V path. Colpotomy will be closed with using 2.0 rapid vicryl.

Surgical removal of both salpinx by conventional laparoscopy in a standardised fashion: with using one 10-mm umbilical and two 5-mm lateral ports.

Sponsors

Bakirkoy Dr. Sadi Konuk Research and Training Hospital
CollaboratorOTHER_GOV
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Women aged over 18 years regardless of parity with a non-prolapsed uterus * Patients who are indicated or seek for definitive surgical sterilisation * Patients who prefers salpingectomy over tubal ligation after considering its possible cancer prevention effect * Written informed consent obtained prior to surgery

Exclusion criteria

* Any malignancy * Suspected rectovaginal endometriosis * History of pelvic inflammatory disease, pouch of Douglas abscess * Being Virgo or Pregnant * Failure to provide written informed consent prior to surgery

Design outcomes

Primary

MeasureTime frameDescription
Patient satisfaction at first weekThe first week after the surgical procedurePatient satisfaction will be measured with Patient Global Impression of Improvement (PGI-I). It is scored as: Very much better (1), Much better (2), A little better (3), No change (4), A little worse (5), Much worse (6), Very much worse (7). Patient reported as Very much better or much better will be regarded as satisfied.
Patient satisfaction at first monthThe first month after the surgical procedurePatient satisfaction will be measured with Patient Global Impression of Improvement (PGI-I). It is scored as: Very much better (1), Much better (2), A little better (3), No change (4), A little worse (5), Much worse (6), Very much worse (7). Patient reported as Very much better or much better will be regarded as satisfied.
Postoperative pain at 6th hoursAt the 6th hours after the surgical procedurePostoperative pain scores will be measured with using Visual Analogue Score (VAS) as self-reported by the participating women. The VAS scores range from 0= no pain to 10= worst imaginable pain.
Postoperative pain at 24th hoursAt the 24th hours after the surgical procedurePostoperative pain scores will be measured with using Visual Analogue Score (VAS) as self-reported by the participating women. The VAS scores range from 0= no pain to 10= worst imaginable pain.

Secondary

MeasureTime frameDescription
Intraoperative complicationsIntraoperativeAny minor and major (e.g., bowel injury, bleeding\>300cc, major vessel injury) complications that occur during the surgery
DyspareuniaAt 1st month after the surgical procedureSubjective Success - Change from baseline Female Sexual Function Index (FSFI) to measure sexual dysfunction at first month. Validated into Turkish language form will be used to compare preoperative and postoperative period. The FSFI is a multiple-trait scoring, self-report document used to assess female sexual function. It consists of 19 items that encompass six separate domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The maximum score is 36 points and the minimum score is 2 points. Only pain subdomain will be used for research purposes.
Postoperative complicationsPostoperative, in the first month of the surgeryAny minor and major complications (e.g., bowel injury, haematoma, infection, dyspareunia, vaginal pain, sexual discomfort) that occur in the first month of the surgery.
Duration of the surgical procedureIntraoperativeDuration of the surgery will be measured in minutes, in between the first vaginal/abdominal incision and vaginal/abdominal wound closure.
ConversionIntraoperativeConversion to laparoscopy or laparotomy will be noted.
Need of AnalgesicsPostoperative, 24 hoursPatients will not be routinely offered additional analgesics and the need of additional analgesics will be noted if patient desires for.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026